natgillin/translations-raw huggingface dataset:
A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound according to claims 1 or 2. 
Pribor koji sadrži spremnik koji sadrži učinkovitu količinu spoja ili njegove farmaceutski prihvatljive soli prema zahtjevu 1 ili 2.
A vaccine comprising an HIV gp140 trimer of any one of claims 1 to 7. 
Cjepivo sadrži HIV gp 140 trimer sukladno patentnim zahtjevima 1 – 7.
The aqueous phase was then extracted into ethyl acetate (290mL and then 145mL). 
Vodenu fazu se zatim ekstrahira u etil-acetat (290 ml, te 145 ml).
C1-C11 substituted or unsubstituted heteroaryl; 
Ci-Ci1 supstituiranog ili nesupstituiranog heteroarila; OR)
The device of clause 6 wherein said heat energy unit is a microwave heater.. 
Sustav prema patentnom zahtjevu 2, naznačen time da je navedeni grijaći uređaj mikrovalni grijač.
The compound of formula (I') of claim 5 for its use according to claim 5, said compound being one or more of the following compounds: 
Spoj formule (T) iz patentnog zahtjeva 5 za njegovu primjenu prema patentnom zahtjevu 5, pri čemu je navedeni spoj jedno ili više od sljedećih spojeva:
A dermal matrix production method (10), characterized by comprising the steps of: 
Postupak dobivanja dermalnog matriksa (10), naznačen time što se sastoji u koracima:
A pharmaceutical composition in accordance with claim 1, wherein the pharmaceutical composition does not contain any lipid. 
Farmaceutski sastav prema zahljevu 1, naznačen time, da taj farmaceutski sastav uopće ne sadrži lipide.
" " is point of attachment; 
"POVE" je točka vezivanja;
The reaction mixture is poured onto water (600 ml) and extracted with 1:1 ethyl acetate/diethyl ether (4×300 ml). 
Reakcijsku smjesu se prelije na vodu (600 ml) i ekstrahira s 1:1 etil acetat/dietil eterom (4 x 300 ml).
The method of any one of claims 1 to 7, wherein R1 and R2 are each independently selected from the group consisting of NH3, methyl amine, ethyl amine, propyl amine, isopropyl amine, butyl amine, cyclohexane amine, aniline, and pyridine; and R3 is 1,2-ethylenediamine or cyclohexane-1,2-diamine. 
Postupak prema bilo kojem od zahtjeva 1 do 7, naznačen time da R1 i R2 su svaki neovisno odabrani iz skupine koju čine NH3, metil amin, etil amin, propil amin, izopropil amin, butil amin, cikloheksan amin, anilin, i piridin, i R3 je 1,2-etilendiamin ili cikloheksan-1,2-diamin.
Preparation of the Compound of Formula (I) 
Datum objave europske prijave patenta:
According to a further feature of this aspect there is disclosed a method for producing an anti-proliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically acceptable salt thereof, as hereinbefore defined. 
Prema dodatnom aspektu ovog izuma, objavljen je postupak za postizanje antiproliferativnog učinka u toplokrvnoj životinji, poput čovjeka, kojoj je takvo liječenje potrebno, a koji se sastoji od davanja spomenutoj životinji efektivne doze derivata kinazolina prikazanog Formulom I, ili njegove farmaceutski prihvatljive soli, u skladu sa definicijom u gornjem tekstu.
Use according to anyone of paras 52 to 56, wherein the receptor comprises the amino acid sequence of a G protein-coupled receptor having at least about 80% identity to SEQ ID NO: 2. 
Uporaba prema bilo kojem zahtjevu od 43 do 54, naznačena time, da receptor sadrži sekvencu amino kiseline od receptora vezanih G-proteina koja ima najmanje oko 80% identiteta od SEQ ID NO:2.
In the experimental part the following abbreviations are used: 
U eksperimentalnom dijelu upotrijebljene su slijedeće kratice:
The coupling system according to claim 1, wherein the respective latching element comprises plastic and/or metal and/or is implemented as a cord, flexible shaft, chain, or strand. 
Sustav za spajanje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se odgovarajući element za zabravljivanje (20) sastoji od plastike i/ili metala i/ili je načinjen kao uže, fleksibilni štap, lanac, ili vrpca.
According to one aspect of the present invention there is provided a composition, including penethamate (PNT) or a pharmaceutical equivalent thereof; and at least one oily vehicle. Preferably the viscosity of the composition is below 3000 mPas at a temperature of 20° C. and shear rate of 1/s measured with a cup cylinder method. 
Pripravak spreman za upotrebu za intramuskularnu ili potkožnu injekciju, koji sadrži 15%-55% m/v penetamat hidrojodida i najmanje jedan uljasti nosač, uključujući etil oleat; naznačen time što je viskoznost pripravka ispod 3000 mPas pri temperaturi od 20%C i brzini smicanja od 1/s izmjereno metodom čaše s cilindrom.
plunger 181 is caused to slide upwards against the reaction force of the counter-spring, thereby acting on the upper concave portion 120 of the lever 114 . 
klip 181, počinje kliziti prema gore, nasuprot sili reakcije protuopruge, djelujući tako na gornji udubljeni dio 120 poluge 114.
providing a further radar detector (406) at a further vessel location (404), different from the vessel location (402); 
- < postavljanje dodatnog radarskog detektora (406) na dodatnom položaju broda (404), koji je različit od položaja
45): Abst 2557) and the compounds claimed in the PCT patent applications number WO03/097613 and PCT/EP03/14722 and in the Spanish patent application number P200302613 . 
45): Abst 2557) i spojevi za koje se traži zaštita u PCT patentnim prijavama br. WO03/097613 1 PCT/EP03/14722 1 španjolskoj patentnoj prijavi br.
wherein the filter element comprises a flange that is attached to the collar edge of the capsule body. 
Kapsula s porcijom (1) prema zahtjevu 1, naznačena time da je element filtera spojen na tijelo kapsule (2).
m is selected from the series consisting of 0 and 1 if X is sulfur or (R10)(R11)C, and m is 1 if X is oxygen; 
m je odabran iz niza koji čine 0 i 1 ako X je sumpor ili (R10)(R11)C, i m je 1 ako X je kisik;
The device according to claim 1, wherein an end of one lever of each pair of levers opposite to the knee joint is respectively connected to one of the first jaw member and the cooperating second jaw member, while the other end is respectively fixed in translation. A device for producing a beverage from a capsule, comprising: 
Uredaj u skladu s patentnim zahtjevom 2 ili 3, kod kojega je krajnji dio jedne poluge (19) svakog para poluga, koji krajnji dio se nalazi na suprotnoj strani od koljenastog spoja (46), na odgovarajući način spojen na jedan od elemenata poluge (6, 7), dok je drugi krajnji dio na odgovarajući način učvršćen na element za translacijsko kretanje.
System according to claim 1 comprising a connected device called a “sensor-actuator” comprising: 
Sustav prema patentnom zahtjevu 1, koji sadrži senzor-aktivator, koji sadrži:
The formulation according to claim 1, further wherein said formulation is hermetically sealed under sterile conditions in a container suitable for storage prior to use. 
Prezentacijski oblik formulacije prema bilo kojem od zahtjeva 1 do 20 naznačen time da je hermetički zatvoren pod sterilnim uvjetima u spremniku koji je pogodan za pohranjivanje prije uporabe.
The apparatus according to one of Claims 5 to 15, characterized in that the second insulator comprises a precipitation facility. 
Uređaj prema jednom od Zahtjeva 5 do 15, naznačen time da drugi izolator sadržava jedinicu za taloženje.
A process for preparing 4-[ethyl(dimethyl)ammonio]butanoate comprising: 
Spoj 4-[etil(dimeti)amonijev]butanoat, naznačen time, da je za uporabu kao lijek.
BACKGROUND OF THE INVENTION Field of the Invention This invention relates to a process for producing a multiplicity of microfluidic arrangements, particularly nozzle arrangements, from a plate-shaped composite structure comprising groove structures with dimensions in the micrometer range and to an atomiser comprising a nozzle arrangement of this type. 
OPIS IZUMA Ovaj izum se odnosi na postupak za proizvodnju više mikrofluidnih naprava, posebno naprava s mlaznicom, od pločaste kompozitne strukture koja ima brazdastu strukturu s dimenzijama u mikrometarskom području, posebno na postupak prema uvodnom dijelu prvog patentnog zahtjeva.
CH3O—(CH2CH2O)n—CH2CH2—OH wherein (n) is an integer from 2 to about 4000, with a composition comprising disuccinimidyl carbonate, wherein the composition comprising the disuccinimidyl carbonate is added such that there is an excess of the disuccinimidyl carbonate relative to the hydroxy-terminated, water-soluble polymer, to thereby result in a composition comprising an active carbonate ester of the water-soluble polymer having the following structure: 
CH:0-(CH2CH20),-CH2CH,2-OH pri čemu (n) je cijeli broj od 2 do 4000, sa kompozicijom koja sadrži disukcinimidil karbonat, pri čemu se kompozicija koja sadrži disukcinimidil karbonat dodaje tako da postoji višak disukcinimidil karbonata u odnosu na vodotopljivi polimer sa hidroksi grupom na kraju lanca, što rezultira kompozicijom koja sadrži aktivni karbonatni ester vodotopljivog polimera koji ima slijedeću strukturu:
the compound according to Claim 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. 
tvar u skladu s bilo kojim od patentnih zahtjeva 5 do 7 ili njenu farmaceutski prihvatljivu sol; i farmaceutski prihvatljivi nosač.
detaching the assembly with adhering sheets from the mould system by moving at least a part of mould plate and/or the upstanding structure away from said assembly with adhered sheets while maintaining the position of at least an other part of mould plate and/or the upstanding structure. 
- < odvajanje sklopa s pričvršćenim plohama iz sustava kalupa pomičući barem dio ploče kalupa i/ili uspravne strukture dalje od navedenog sklopa s pričvršćenim plohama dok se zadržava pozicija barem drugog dijela ploče kalupa i/ili uspravne strukture.
Initial data from a cytotoxicity study on the compound where R8=R9=H in Figure 9 suggested that there was good activity for the acetal. 
Početni podaci iz studije citotoksičnosti spoja gdje Re=Ro=H na slici 9 sugerirali su da je postojala dobra aktivnost za acetal.
a frequency deinterleaver(r709) configured to frequency deinterleave constellation values corresponding to Physical Layer Pipe data referred to as PLP data; 
dio za raspletanje frekvencije (r709) konfiguriran za raspletanje frekvencije konstelacijskih vrijednosti koje odgovaraju PLP podatku;
growing said plant under conditions wherein the temperature is higher than ambient environmental temperature for at least two consecutive hours per day for at least four days following contact with said glyphosate, wherein said days following contact is within the growing season of the plant. 
C) uzgoj navedene biljke pod uvjetima u kojima je temperature viša od temperature okoliša tijekom najmanje dva uzastopna sata dnevno u razdoblju od najmanje četiri dana nakon dovođenja u kontakt s glifosfatom, pri čemu su navedeni dani nakon kontakta u razdoblju rasta biljke.
A separate dispensing head that contains a pressure regulator can be connected by the user to a beer dispensing valve and to a CO2 feed valve of the beer keg. 
Odvojena glava raspršivača, koja sadrži regulator pritiska, korisnik može spojiti na ventil za raspršivanje te na dovodni ventil CO, bačvice piva.
the palladium catalyst comprises a palladium-XPhos complex, wherein XPhos is 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl; and the base is a phosphate base or a carbonate base. 
paladijski katalizator uključuje kompleks paladij-XPhos, gdje je XPhos 2-dicikloheksilfosfino-2′,4′,6′-triizopropilbifenil; i baza je fosfatna baza ili karbonatna baza.
providing an aminooxy compound comprising an aminooxy group and a second reactive group wherein the second reactive group is chosen from hydrazine, hydrazide, semicarbazide, thiosemicarbazide, amine, carboxyl, ester, acyl halide, acyl azide, alkyl halide, anhydride, isothiocyanate, isocyanate and sulfonyl halide groups; and 
osiguravanje aminooksi spoja koji sadrži aminooksi skupinu i drugu reaktivnu skupinu pri čemu je druga reaktivna skupina odabrana od hidrazina, hidrazida, semikarbazida, tiosemikarbazida, amina, karboksila, estera, acil halogenida, acil azida, alkil halogenida, anhidridne, izotiocijanatne, izocijanatne i sulfonil halogenidne skupine; i
<400> 11 A tumour associated peptide according to SEQ ID No. 
Peptid povezan s tumorom sukladno SEQ ID br.
In a further embodiment, X is 4-pyridinyl optionally substituted with one group selected from C1-C4 alkyl, cyclopropyl, cyclopropyloxy, cyclopropylmethyl, C1-C4 alkoxy, CF3, amino, alkylamino, dialkylamino, thioalkyl, halogen, alkylsulfonyl and cyano. 
Spoj prema zahtjevu 8, naznačen time da je X 4-piridinil opcionalno supstituiran jednim supstituentom izabranim iz skupine koju sačinjavaju C;-C4 alkil, ciklopropil, ciklopropiloksi, ciklopropilmetil, C,-Ca alkoksi, CF3, amino, alkilamino, dialkilamino, tioalkil, halogen, alkilsulfonil i cijano.
Separate dosage forms or a package according to any of claims 7-9, wherein said second agent is for simultaneous administration. 
Zasebni dozirni oblici ili pakiranje prema bilo kojem od zahtjeva 9-11, gdje je to drugo sredstvo za istodobnu primjenu.
The water soluble taxane derivative according to claim 1, characterized in that in general formula (I-1), is H, R2 is acetyl, and R3 is phenyl; 
2. - Derivat taksana topiv u vodi u skladu s patentnim zahtjevom 1, naznačen time što u općoj formuli (I-1), R' je H, R' je acetil, a R? je fenil;
represents a hydrogen atom, a C1-4 alkoxy carbonyl group, a C3-6 cycloalkyl carbonyl group, a benzoyl group, a C1-6 alkyl group, the groups being optionally substituted by 1 to 4 substituents selected from a halogen atom, a hydroxyl group or a C1-4 alkoxy group; o and m represent 1 to 2; n represents 0 to 3; 
R4 predstavlja atom vodika, C,4 alkoksikarbonilnu skupinu, C3.4 cikloalkilkarbonilnu skupinu, benzoilnu skupinu, Cig alkilnu skupinu, gdje su te skupine izborno supstituiran s 1 do 4 supstituenta, koje se bira između atoma halogena, hidroksilne skupine ili C;.4 alkoksi skupine; oimznače 1 do 2; n znači 0 do 3; pznači 0 do 2;1 q znači 0 do 2.
The pharmaceutical composition according to claim 15, wherein the pharmaceutical composition comprises about 0.5 mg to about 1000 mg of the crystalline Form A of 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 7-9, naznačen time da navedeni farmaceutski pripravak sadrži od 0.5 mg do 1000 mg kristalnog 4-[7-(6-cijano-5-trifluorometilpiridin-3-11)-8-okso-6-tiokso-5,7-diazaspiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamida.
wherein the solubility of water in the ether solvent of (i) or (ii) that has low miscibility with water is less than 5% w/w; and wherein the ether solvent of (i) or (ii) that has low miscibility with water constitutes at least 70% v/v of the reaction mixture; 
ko-otapalo čini ne više od 20% vol./vol. reakcijske smjese; pri čemu je otopljivost vode u eterskom otapalu (i) ili (1i) koji ima nisku mješavost sa vodom manja od 5% tež./tež.;i pri čemu etersko otapalo (1) ili (ii) koje ima nisku otopljivost sa vodom čini najmanje 70% vol./vol. reakcijske smjese;
The composition for use according to claim 1, further comprising at least one compound selected from sulfisoxazole, methimazole, prilocaine, dyphylline, quinacrine, carbenoxolone, aminocaproic acid, cabergoline, diethylcarbamazine, cinacalcet, cinnarizine, eplerenone, fenoldopam, leflunomide, levosimendan, sulodexide, terbinafine, zonisamide, etomidate, phenformin, trimetazidine, mexiletine, ifenprodil, moxifloxacin, bromocriptine or torasemide, or pharmaceutically acceptable salts thereof. 
Smjesa za uporabu prema zahtjevu 1, dalje sadrži barem jedan dodatni spoj izabran iz grupe koja obuhvaća sulfizoksazol, metimazol, prilokain, difiln, kvinakrin, karbenoksolon, aminokaproičnu kiselinu, kabergolin, dietilkarbamazin, sinakalcet, cinarizin, eplerenon, fenoldopam, leflunomid, levosimendan, sulodeksid, terbinafin, zonisamid, etomidat, fenformin, trimetazidin, meksiletin, ifenprodil, moksifloksacin, bromokriptin ili torasemid, ili njihove farmaceutski prihvatljive soli.
and R3 are independently halogen, or C1-C6 alkyl wherein said C1-C6 alkyl is substituted with 0-6 halogen; 
i R3 su neovisno halogen ili skupina C1-C6 alkil, pri čemu je navedena skupina C1-C6 alkil supstituirana s 0-6 halogena;
In addition, since the portion protruding into the data portion of the attachment portion is dimensioned such that it barely extends at all or extends only slightly to the data area of the data portion, in which the data of the data sheet is recorded, the risk of providing the data area with such a layer structure that would enable to disassemble the data sheet in the data area is avoided. 
Dodatno tome, budući da je predio koji strši u predio za podatke predjela za povezivanje dimenzioniran tako da on uopće ne ulazi ili ulazi samo neznatno u prostor za podatke predjela za podatke u kojemu su zapisani podaci lista za podatke, spriječen je rizik od dolaženja do područja za podatke, koje područje ima takvu izvedbu sloja, koja izvedba bi onemogućila rastavljanje lista za podatke u području za podatke.
The umbrella as recited in claim 1, wherein an end of each respective umbrella strut element oriented toward the central holding element is substantially pyramid-shaped, a cross-sectional area of each respective umbrella strut element forms a base of a pyramid, a respective contact surface of the respective umbrella strut element and the central holding element is situated on a first side surface of the pyramid, a contact surface of the respective umbrella strut element and an umbrella strut element adjoining it on a first side is situated on a second side surface of the pyramid, and a contact surface of the respective umbrella strut element and an umbrella strut element adjoining it on a second side is situated on a third side surface of the pyramid. 
Kišobran kao što je navedeno u patentnom zahtjevu 1, naznačen time da je završetak svakog odgovarajućeg potpornog elementa kišobrana orijentiran prema središnjem elementu držača izveden uglavnom u obliku piramide, površina poprečnog presjeka odgovarajućeg potpornog elementa kišobrana tvori osnovicu piramide, odgovarajuća dodirna površina odgovarajućeg potpornog elementa kišobrana i središnjeg elementa držača smještena je na prvoj strani površine piramide, dodirna točka odgovarajućeg potpornog elementa kišobrana i potpornog elementa kišobrana koji se nadovezuje na prvu stranu side smještena je na drugoj strani površine piramide, a dodirna točka odgovarajućeg potpornog elementa kišobrana i potpornog elementa kišobrana koji se nadovezuje na drugu stranu smještena je na trećoj strani površine piramide.
Metazachlor herein shall mean 2-Chloro-(2',6'-dimethyl-N-pyrazol-1-yl-methyl)-acetamid in all of his crystal modifications, in particular the monoclinic Metazachlor which is described in EP 0 411 408 A (BASF Aktiengesellschaft). 
Metazaklor ovdje označava 2-kloro-(2',6'-dimetil-N-pirazol-1-il-metil)-acetamid u svim njegovim kristalnim modifikacijama, posebno monoklinasti metazaklor koji je opisan u EP 0 411 408 A (BASF Aktiengesellschaft).
If desired, the protected sulfide compound could also have been taken directly into oxidation step (a). 
Ako se želi, zaštitni sulfidni spoj može se prenijeti direktno u oksidacijski korak (a).
After stirring at room temperature for I hour, the reaction was quenched with 1N HCl (100 mL). 
Nakon miješanja na sobnoj temperaturi tijekom jednog sata, reakcija se prekine s IN HCI (100 mL).
obtain the value of at least one digital information item that is different from those obtained by entropy decoding, from the calculated value. 
- < rekonstrukcije, iz navedenog izračunatog pariteta, vrijednosti predznaka preostale stavke podatka iz podskupa.
A method for inhibiting anti-apoptotic Bcl-2 protein function in a cell comprising contacting a cell comprising anti-apoptotic Bcl-2 protein with the compound or therapeutically acceptable salt of claim 2 . 
Farmaceutski pripravak, naznačen time, da sadržava inertni nosač 1 terapeutski učinkovitu količinu spoja ili terapeutski prihvatljivu sol u skladu s patentnim zahtjevom 1 ili 2.
administering to the subject a therapeutically effective amount of a compound comprising a peptide and a conjugating group, wherein the peptide consists of an amino acid sequence having the formula X1-X2-X3-X4-X5-X6-X7, wherein 
Spoj, koji obuhvaća peptid i konjugirajuću skupinu, gdje peptid sadrži aminokiselinsku sekvencu formule: [image] gdje
the soluble hyaluronidase is administered separately from the IG prior to administration of the IG and at the same site as the IG; 
topiva hijaluronidaza se daje odvojeno od IG prije davanja IG i na istom mjestu kao IG;
An FGF-18 compound for use in the treatment of a cartilage disorder wherein the FGF-18 compound is to be administered intra-articularly at least three times per treatment cycle, said administrations being separated by about 3, 4 or 5 weeks. 
HR P20181572 T1 PATENTNI ZAHTJEVI Spoj FGF-18 za uporabu u liječenju poremećaja hrskavice naznačen time što se spoj FGF-18 treba primijeniti intra-artikularno barem tri puta po ciklusu terapije, te su navedene primjene odvojene za oko 2 tjedna.
a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:360; or 
slijed aminokiselina kodiran polinukleotidnim slijedom koji hibridizira pod umjereno strogim uvjetima s komplementarnim polinukleotidom koji se sastoji od SEQ ID NO:360;
enclosing said assembly (3) under a cover layer (10) in a sealing manner with respect to the mould (1), 
- < zatvaranje sklopa (3) pod pokrov (10) na način da se zatvori u odnosu na kalup (1),
Alzheimer's disease, Pick's disease, Progressive Supranuclear Palsy (PSP), fronto-temporal dementia, fronto-temporal dementia with parkinsonism linked to chromosome 17, disinhibition-dementia-parkinsonism-amyotrophy complex, pallido-ponto-nigral degeneration, Guam-ALS syndrome; pallido-nigro-luysian degeneration, cortico-basal degeneration, or 
Alzheimerova bolest, Pickova bolest, progresivna supranuklearna palsija (PSP), fronto-temporalna demencija, fronto-temporalna demencija s parkinsonizmom povezanim s kromosomom 17, mješavina disinhibicije, demencije, parkinsonizma i amiotrofije, palido-ponto-nigralna degeneracija, sindrom Guam-ALS, palido- nigro-luizijanska degeneracija, kortiko-bazalna degeneracija, ili
The polypeptide dimer of any one of claims 1 to 6, wherein the soluble gp130 molecule or variant or fragment thereof is directly fused to the hinge region of the Fc domain of the IgG1 protein or via a flexible polypeptide linker. 
Polipeptidni dimer prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time što je topljiva gp130 molekula ili njena varijanta direktno fuzionirana sa zglobnom regijom Fc domene IgG1 proteina ili preko fleksibilne polipeptidne poveznice.
Sgopb, denoting the average non-reference b frame sizes per GOP; 
Sžop » koji označuje prosjek veličina nereferentnog b kadra po GOP-u;
The composition according to claims 1 or 2, wherein the drug/polymer mass ratio is about 33%. 
Sastav u skladu sa zahtjevom 3 gdje je omjer mase lijeka/polimera otprilike 33%.
For melting the plastic coating it is sufficient to only heat the coating at the location or locations where the bonds are to be formed but it is also possible to, for example, heat an entire annular strip of the plastic coating. 
Za topljenje odgovarajuće plastične obloge dovoljno je zagrijati oblogu samo lokalno, ali je također moguće, na primjer, da se plastična obloga, kao prstenasta traka, kompletno zagrije.
The pharmaceutical composition of claim 20 for administration by inhalation. 
Farmaceutski pripravak prema patentnom zahtjevu 12, naznačen time da je pogodan za davanje inhalacijom.
• are separated from said movement group by means of a wall (3) of said double glazing (1); 
* je odvojen od navedene skupine za pokretanje stijenkom (3), koju čini navedeno dvostruko ostakljenje (1);